Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome

V. Jayagopal, E. S. Kilpatrick, S. Holding, P. E. Jennings, Stephen Atkin

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The objective of this study was to evaluate and compare the effect of treatment with orlistat vs. metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS). Twenty-one Caucasian women with PCOS [mean (±SEM) age 27 ± 0.9 yr and body mass index 36.7 ± 3.3 kg/m2] participated in this prospective, randomized, open-labeled study. All subjects had an 8-wk run-in period of dietary modification and then randomized to receive either metformin (500 mg three times daily) or orlistat (120 mg three times daily) for 3 months. Weight, blood pressure, and fasting blood samples were taken at screening, randomization, and on completion. Insulin resistance (IR) was calculated using the homeostasis model of assessment (HOMA)-IR method [HOMA-IR = (insulin × glucose)/22.5]. The results are expressed as mean ± SEM. When compared with baseline, treatment with both orlistat [93.5 ± 11.5 ng/dl (3.24 ± 0.4 nmol/liter) vs. 114.5 ± 11.5 ng/dl (3.97 ± 0.4 nmol/liter), P = 0.039] and metformin [97.2 ± 11.5 ng/dl (3.37 ± 0.4 nmol/liter) vs. 120.0 ± 8.7 ng/dl (4.16 ± 0.3 nmol/liter), P = 0.048] produced a significant reduction in total testosterone. Treatment with orlistat produced a 4.69% reduction in weight (99.0 ± 6.0 vs. 94.6 ± 6.1 kg, P = 0.002), and this reduction was more significant than the reduction produced by metformin (4.69 vs. 1.02%, P = 0.006). There was no significant reduction seen after either treatment group for fasting insulin, HOMAIR, SHBG, or any of the lipid parameters studied. In this study, orlistat produced a significant reduction in weight and total testosterone. The reduction in total testosterone was similar to that seen after treatment with metformin. Therefore, orlistat may prove to be a useful adjunct in the treatment of PCOS.

Original languageEnglish
Pages (from-to)729-733
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number2
DOIs
Publication statusPublished - Feb 2005
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Metformin
Insulin
Insulin Resistance
Testosterone
Weight Loss
Fasting
Homeostasis
Therapeutics
Diet Therapy
Scanning electron microscopy
Random Allocation
Blood pressure
orlistat
Body Mass Index
Screening
Blood
Blood Pressure
Lipids
Weights and Measures

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. / Jayagopal, V.; Kilpatrick, E. S.; Holding, S.; Jennings, P. E.; Atkin, Stephen.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 90, No. 2, 02.2005, p. 729-733.

Research output: Contribution to journalArticle

Jayagopal, V. ; Kilpatrick, E. S. ; Holding, S. ; Jennings, P. E. ; Atkin, Stephen. / Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2005 ; Vol. 90, No. 2. pp. 729-733.
@article{c9d30a8aaef0487088986ea5a62c9c25,
title = "Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome",
abstract = "The objective of this study was to evaluate and compare the effect of treatment with orlistat vs. metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS). Twenty-one Caucasian women with PCOS [mean (±SEM) age 27 ± 0.9 yr and body mass index 36.7 ± 3.3 kg/m2] participated in this prospective, randomized, open-labeled study. All subjects had an 8-wk run-in period of dietary modification and then randomized to receive either metformin (500 mg three times daily) or orlistat (120 mg three times daily) for 3 months. Weight, blood pressure, and fasting blood samples were taken at screening, randomization, and on completion. Insulin resistance (IR) was calculated using the homeostasis model of assessment (HOMA)-IR method [HOMA-IR = (insulin × glucose)/22.5]. The results are expressed as mean ± SEM. When compared with baseline, treatment with both orlistat [93.5 ± 11.5 ng/dl (3.24 ± 0.4 nmol/liter) vs. 114.5 ± 11.5 ng/dl (3.97 ± 0.4 nmol/liter), P = 0.039] and metformin [97.2 ± 11.5 ng/dl (3.37 ± 0.4 nmol/liter) vs. 120.0 ± 8.7 ng/dl (4.16 ± 0.3 nmol/liter), P = 0.048] produced a significant reduction in total testosterone. Treatment with orlistat produced a 4.69{\%} reduction in weight (99.0 ± 6.0 vs. 94.6 ± 6.1 kg, P = 0.002), and this reduction was more significant than the reduction produced by metformin (4.69 vs. 1.02{\%}, P = 0.006). There was no significant reduction seen after either treatment group for fasting insulin, HOMAIR, SHBG, or any of the lipid parameters studied. In this study, orlistat produced a significant reduction in weight and total testosterone. The reduction in total testosterone was similar to that seen after treatment with metformin. Therefore, orlistat may prove to be a useful adjunct in the treatment of PCOS.",
author = "V. Jayagopal and Kilpatrick, {E. S.} and S. Holding and Jennings, {P. E.} and Stephen Atkin",
year = "2005",
month = "2",
doi = "10.1210/jc.2004-0176",
language = "English",
volume = "90",
pages = "729--733",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome

AU - Jayagopal, V.

AU - Kilpatrick, E. S.

AU - Holding, S.

AU - Jennings, P. E.

AU - Atkin, Stephen

PY - 2005/2

Y1 - 2005/2

N2 - The objective of this study was to evaluate and compare the effect of treatment with orlistat vs. metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS). Twenty-one Caucasian women with PCOS [mean (±SEM) age 27 ± 0.9 yr and body mass index 36.7 ± 3.3 kg/m2] participated in this prospective, randomized, open-labeled study. All subjects had an 8-wk run-in period of dietary modification and then randomized to receive either metformin (500 mg three times daily) or orlistat (120 mg three times daily) for 3 months. Weight, blood pressure, and fasting blood samples were taken at screening, randomization, and on completion. Insulin resistance (IR) was calculated using the homeostasis model of assessment (HOMA)-IR method [HOMA-IR = (insulin × glucose)/22.5]. The results are expressed as mean ± SEM. When compared with baseline, treatment with both orlistat [93.5 ± 11.5 ng/dl (3.24 ± 0.4 nmol/liter) vs. 114.5 ± 11.5 ng/dl (3.97 ± 0.4 nmol/liter), P = 0.039] and metformin [97.2 ± 11.5 ng/dl (3.37 ± 0.4 nmol/liter) vs. 120.0 ± 8.7 ng/dl (4.16 ± 0.3 nmol/liter), P = 0.048] produced a significant reduction in total testosterone. Treatment with orlistat produced a 4.69% reduction in weight (99.0 ± 6.0 vs. 94.6 ± 6.1 kg, P = 0.002), and this reduction was more significant than the reduction produced by metformin (4.69 vs. 1.02%, P = 0.006). There was no significant reduction seen after either treatment group for fasting insulin, HOMAIR, SHBG, or any of the lipid parameters studied. In this study, orlistat produced a significant reduction in weight and total testosterone. The reduction in total testosterone was similar to that seen after treatment with metformin. Therefore, orlistat may prove to be a useful adjunct in the treatment of PCOS.

AB - The objective of this study was to evaluate and compare the effect of treatment with orlistat vs. metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS). Twenty-one Caucasian women with PCOS [mean (±SEM) age 27 ± 0.9 yr and body mass index 36.7 ± 3.3 kg/m2] participated in this prospective, randomized, open-labeled study. All subjects had an 8-wk run-in period of dietary modification and then randomized to receive either metformin (500 mg three times daily) or orlistat (120 mg three times daily) for 3 months. Weight, blood pressure, and fasting blood samples were taken at screening, randomization, and on completion. Insulin resistance (IR) was calculated using the homeostasis model of assessment (HOMA)-IR method [HOMA-IR = (insulin × glucose)/22.5]. The results are expressed as mean ± SEM. When compared with baseline, treatment with both orlistat [93.5 ± 11.5 ng/dl (3.24 ± 0.4 nmol/liter) vs. 114.5 ± 11.5 ng/dl (3.97 ± 0.4 nmol/liter), P = 0.039] and metformin [97.2 ± 11.5 ng/dl (3.37 ± 0.4 nmol/liter) vs. 120.0 ± 8.7 ng/dl (4.16 ± 0.3 nmol/liter), P = 0.048] produced a significant reduction in total testosterone. Treatment with orlistat produced a 4.69% reduction in weight (99.0 ± 6.0 vs. 94.6 ± 6.1 kg, P = 0.002), and this reduction was more significant than the reduction produced by metformin (4.69 vs. 1.02%, P = 0.006). There was no significant reduction seen after either treatment group for fasting insulin, HOMAIR, SHBG, or any of the lipid parameters studied. In this study, orlistat produced a significant reduction in weight and total testosterone. The reduction in total testosterone was similar to that seen after treatment with metformin. Therefore, orlistat may prove to be a useful adjunct in the treatment of PCOS.

UR - http://www.scopus.com/inward/record.url?scp=14044255980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044255980&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-0176

DO - 10.1210/jc.2004-0176

M3 - Article

C2 - 15536162

AN - SCOPUS:14044255980

VL - 90

SP - 729

EP - 733

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -